中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(3): 556-559

Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.03.011

  • Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

  • Received Date: 2020-09-12
  • Accepted Date: 2020-10-06
  • Published Date: 2021-03-20
    Abstract
  •   Objective  To investigate the influencing factors for persistent low-level viremia (LLV) in chronic hepatitis B(CHB) patients receiving long-term entecavir antiviral therapy.  Methods  The CHB patients who received entecavir antiviral therapy for at least one year in The Affiliated Hospital of Xuzhou Medical University from November 2018 to June 2020 were enrolled as subjects, and according to HBV DNA load at the end of the observation period, the patients were divided into LLV group and sustained virological response (SVR) group. Demographic features and laboratory markers were observed for all patients. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. A multivariate logistic regression analysis was used to investigate the influencing factors for LLV in patients receiving long-term entecavir treatment.  Results  A total of 560 CHB patients were enrolled, with 204 in the LLV group and 356 in the SVR group. There were significant differences between the two groups in age (Z=-3.530, P < 0.001), sex (χ2=4.270, P=0.039), presence or absence of liver cirrhosis (χ2=53.879, P < 0.001), medication compliance (χ2=5.326, P=0.021), HBeAg positive rate (χ2=90.681, P < 0.001), baseline HBV DNA load before treatment (Z=-8.337, P < 0.001), baseline HBsAg quantification (Z=-10.472, P < 0.001), and medication type (χ2=7.558, P=0.006). The multivariate logistic regression analysis showed that baseline HBeAg status before treatment (odds ratio [OR]=3.381, 95% confidence interval [CI]: 1.985-5.756, P < 0.001), HBV DNA load before treatment (OR=1.223, 95%CI: 1.050-1.424, P=0.010), and HBsAg quantification before treatment (OR=2.448, 95%CI: 1.743-3.438, P < 0.001) were risk factors for LLV in long-term entecavir antiviral therapy.  Conclusion  In clinical practice, CHB patients with high HBV DNA load, high HBsAg quantification, and positive HBeAg tend to have a high risk of LLV even after long-term entecavir antiviral therapy. Therefore, such population should be taken seriously with the dynamic monitoring of HBsAg quantification, HBV DNA load, and HBeAg status.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
    [2]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
    [3]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021
    [4]
    OGAWA E, NOMURA H, NAKAMUTA M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7): 1578-1589. DOI: 10.1111/liv.14482
    [5]
    KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916
    [6]
    LU JH, YANG L, ZHAO ZX, et al. Comparative study of high-sensitivity and ordinary fluorescence quantitative PCR in monitoring antiviral efficacy of patients with chronic hepatitis B[J]. J Mol Diagn Ther, 2019, 11(5): 361-364. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YXYQ201905004.htm

    卢建华, 杨莉, 赵召霞, 等. 高敏与普通荧光定量PCR技术在慢乙肝患者抗病毒疗效监测中的对比研究[J]. 分子诊断与治疗杂志, 2019, 11(5): 361-364. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYQ201905004.htm
    [7]
    KIM HJ, CHO YK, JEON WK, et al. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience[J]. Clin Mol Hepatol, 2017, 23(4): 323-330. DOI: 10.3350/cmh.2017.0005
    [8]
    HUANG YJ, YANG SS, YEH HZ, et al. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B[J]. PLoS One, 2019, 14(8): e0221958. DOI: 10.1371/journal.pone.0221958
    [9]
    SUN Y, WU X, ZHOU J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591. DOI: 10.1016/j.cgh.2020.03.001
    [10]
    SHIN JW, JUNG SW, LEE SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir[J]. Am J Gastroenterol, 2018, 113(7): 998-1008. DOI: 10.1038/s41395-018-0093-9
    [11]
    LIN L, LIU JY, DENG H, et al. Influencing factors of partial virological response to entecavir monotherapy of patients with chronic hepatitis B[J/CD]. Chin J Liver Dis (Electronic Version), 2019, 11(4): 81-84. (in Chinese)

    林丽, 刘俊英, 邓慧, 等. 恩替卡韦单药治疗慢性乙型肝炎患者部分病毒学应答的影响因素[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(4): 81-84.
    [12]
    GORDON SC, KRASTEV Z, HORBAN A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load[J]. Hepatology, 2013, 58(2): 505-513. DOI: 10.1002/hep.26277
    [13]
    QIU Q, YU HY, PAN J, et al. Antiviral efficacy of entecavir for the treatment of chronic hepatitis B[J]. J Southeast Univ (Med Sci Edi), 2010, 29(6): 685-688. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-NJTD201006025.htm

    裘强, 俞海英, 潘剑, 等. 恩替卡韦治疗慢性乙型肝炎疗效观察[J]. 东南大学学报(医学版), 2010, 29(6): 685-688. https://www.cnki.com.cn/Article/CJFDTOTAL-NJTD201006025.htm
    [14]
    HE LF, LONG YS, ZHANG HY. Correlation study between hepatitis B virus DNA replication level and HBeAg and HBsAg[J]. Clin Med Eng, 2020, 27(1): 65-66. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YBQJ202001033.htm

    何龙芳, 龙云升, 张海业. 乙型肝炎病毒DNA复制水平与HBeAg、HBsAg的相关性研究[J]. 临床医学工程, 2020, 27(1): 65-66. https://www.cnki.com.cn/Article/CJFDTOTAL-YBQJ202001033.htm
    [15]
    LEE JM, AHN SH, KIM HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir[J]. Hepatology, 2011, 53(5): 1486-1493. DOI: 10.1002/hep.24221
    [16]
    CHANG ML, CHIEN RN, YEH CT, et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B[J]. J Hepatol, 2005, 43(1): 72-77. DOI: 10.1016/j.jhep.2005.02.021
    [17]
    ZHANG N. The clinical significance of HBsAg quantitative level in HBeAg-negative patients with chronic HBV infection[D]. Yan'an: Yan'an University, 2020. (in Chinese)

    张楠. HBsAg定量水平在HBeAg阴性慢性HBV感染者中的临床意义[D]. 延安: 延安大学, 2020.
    [18]
    SONG JC, MIN BY, KIM JW, et al. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B[J]. Korean J Hepatol, 2011, 17(4): 268-273. DOI: 10.3350/kjhep.2011.17.4.268
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (644) PDF downloads(124) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return